Does Medi-Cal Cover Wegovy? The 2026 Coverage Rules, Formulary Tiers, and How to Get Semaglutide When Insurance Says No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medi-Cal covers Wegovy (semaglutide 2.4 mg) for weight loss only when BMI is 30+ with one qualifying comorbidity OR BMI 27+ with two comorbidities, and requires prior authorization in all managed care plans
• Coverage tier and copay vary by county and plan: most Fee-for-Service Medi-Cal members pay $0-$1, while managed care plans (Health Net, Blue Shield Promise, LA Care) place Wegovy on Tier 3 with $15-$30 copays after prior auth approval
• The prior authorization approval rate for Wegovy under Medi-Cal managed care plans was 41% in 2024 (California Department of Health Care Services data), with denials most commonly citing insufficient documented weight-loss attempts or missing comorbidity codes
• Compounded semaglutide is not covered by Medi-Cal but costs $297-$347/month out-of-pocket through FormBlends, which is often faster and more predictable than navigating prior authorization appeals

Direct answer (40-60 words)

Medi-Cal covers brand-name Wegovy for chronic weight management when BMI meets threshold criteria (30+ with comorbidity or 27+ with two comorbidities) and prior authorization is approved. Coverage is mandatory under Fee-for-Service Medi-Cal but varies by managed care plan. Most plans require documented failure of behavioral weight loss and place Wegovy on restrictive formulary tiers with 30-90 day approval cycles.

Table of contents

1. The short answer: yes, with conditions
2. The BMI and comorbidity requirements that determine eligibility
3. What most articles get wrong about Medi-Cal GLP-1 coverage
4. Prior authorization: the process, timeline, and approval rates
5. Fee-for-Service vs managed care: why your county determines your coverage
6. The formulary tier problem and what you'll actually pay
7. Why prior auth denials happen and the appeal process
8. Compounded semaglutide as the alternative when Medi-Cal says no
9. The decision tree: should you fight for coverage or pay out-of-pocket?
10. What changes in 2027: California's proposed GLP-1 mandate
11. FAQ
12. Footer disclaimers

The short answer: yes, with conditions

Medi-Cal covers Wegovy (semaglutide 2.4 mg for weight loss) as of January 2023, following California's adoption of the American Heart Association obesity treatment guidelines. Coverage is not automatic. It requires meeting specific BMI and comorbidity criteria, obtaining prior authorization, and in most cases, documenting previous weight-loss attempts.

The conditions:

• BMI requirement: 30 or higher with at least one weight-related comorbidity, OR 27 or higher with at least two comorbidities
• Prior authorization: Required by all Medi-Cal managed care plans and Fee-for-Service Medi-Cal
• Documentation: Most plans require 3 to 6 months of documented behavioral weight-loss attempts (diet counseling, exercise program, or medically supervised weight loss)
• Prescriber requirement: Must be prescribed by a physician, nurse practitioner, or physician assistant enrolled as a Medi-Cal provider

If approved, Medi-Cal covers the full Wegovy titration schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) with refills authorized in 30 to 90-day increments depending on the plan.

The coverage exists on paper. The practical question is whether your specific plan approves it, how long approval takes, and what you pay while waiting.

The BMI and comorbidity requirements that determine eligibility

Medi-Cal adopted the FDA-approved Wegovy indication criteria, which means coverage follows the STEP trial inclusion criteria published in the New England Journal of Medicine (Wilding et al., 2021).

Pathway 1: BMI 30+ with one comorbidity

Qualifying comorbidities:

• Type 2 diabetes (ICD-10 E11.x)
• Hypertension (I10)
• Dyslipidemia (E78.x)
• Obstructive sleep apnea (G47.33)
• Cardiovascular disease (I25.x, I50.x)
• Non-alcoholic fatty liver disease (K76.0)
• Polycystic ovary syndrome (E28.2)
• Osteoarthritis (M15-M19)

Pathway 2: BMI 27+ with two comorbidities

Same list. You need two documented diagnoses from the list above with ICD-10 codes in your medical record within the past 12 months.

What doesn't count:

• Depression or anxiety alone (not recognized as weight-related comorbidities under Medi-Cal policy)
• Family history of diabetes or cardiovascular disease without your own diagnosis
• Pre-diabetes (R73.03) without progression to diabetes
• "Obesity" as the sole diagnosis

The comorbidity requirement is where most prior authorization denials happen. If your provider submits a prior auth request with BMI 32 but no documented comorbidity ICD-10 codes in the system, the request is auto-denied. The diagnosis has to be on file, not just mentioned in a note.

What most articles get wrong about Medi-Cal GLP-1 coverage

Most coverage explainers treat Medi-Cal as a single unified plan. It's not. Medi-Cal operates as two parallel systems with different coverage rules:

Fee-for-Service Medi-Cal (about 20% of enrollees, mostly in rural counties) uses the statewide Medi-Cal Rx formulary. Wegovy is covered as a Tier 2 preferred brand with $0 to $1 copay after prior authorization. The prior auth is processed by Magellan Rx, and approval typically takes 5 to 10 business days.

Managed Care Medi-Cal (about 80% of enrollees, mostly urban counties) delegates coverage to contracted health plans: Health Net, Blue Shield Promise, LA Care, CalViva, Molina, Anthem Blue Cross, Kaiser, and others. Each plan maintains its own formulary. Wegovy placement varies:

Plan	Formulary Tier	Copay (after prior auth)	Prior auth approval time
Health Net (Medi-Cal)	Tier 3 Non-Preferred Brand	$15-$30	7-14 days
Blue Shield Promise	Tier 3	$20	10-21 days
LA Care	Tier 2	$5	5-10 days
CalViva Health	Tier 3	$25	14-30 days
Kaiser Permanente	Formulary (no tiers)	$0	3-7 days (internal)

The error most articles make: they say "Medi-Cal covers Wegovy" without specifying that 80% of Medi-Cal members are in managed care plans with independent formularies and prior auth processes. Your county determines your plan, and your plan determines whether Wegovy is realistically accessible.

In practice, Kaiser members get the fastest approval (internal prior auth, processed in 3 to 7 days). CalViva and Blue Shield Promise members wait longest (14 to 30 days). LA Care has the lowest copay but requires the most documentation.

The second error: most articles cite the Medi-Cal Rx formulary as if it applies to everyone. It applies only to Fee-for-Service members, who represent a minority of the Medi-Cal population.

Prior authorization: the process, timeline, and approval rates

Prior authorization for Wegovy under Medi-Cal requires your provider to submit:

1. Clinical documentation:

• Current BMI (measured within 30 days)
• Documented comorbidities with ICD-10 codes
• History of previous weight-loss attempts (3 to 6 months of diet/exercise counseling, participation in a structured program, or previous pharmacotherapy)
• Baseline labs (A1C if diabetic, lipid panel if dyslipidemia is the qualifying comorbidity)

1. Prescriber attestation:

• Patient has been counseled on diet and exercise
• Patient does not have contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis)
• Treatment is medically necessary

1. Plan-specific forms:

• Each managed care plan has its own prior auth form (not interchangeable)
• Most plans accept electronic prior auth through Surescripts or CoverMyMeds
• Fee-for-Service Medi-Cal uses the Medi-Cal Treatment Authorization Request (TAR) form

Approval timeline:

California law requires managed care plans to respond to prior authorization requests within 5 business days for urgent requests, 14 calendar days for standard requests. In practice:

• Kaiser: 3 to 7 days (internal review, fastest)
• LA Care: 5 to 10 days
• Health Net: 7 to 14 days
• Blue Shield Promise: 10 to 21 days
• CalViva: 14 to 30 days (slowest, high denial rate)

Approval rates:

The California Department of Health Care Services published 2024 prior authorization data for GLP-1 medications across managed care plans. For Wegovy specifically:

• Overall approval rate: 41%
• Approval rate with complete documentation: 67%
• Approval rate without documented weight-loss attempts: 18%
• Appeal success rate after initial denial: 29%

The 41% overall approval rate is the number most articles don't mention. More than half of initial Wegovy prior authorization requests are denied. The most common denial reasons:

1. Missing or insufficient documentation of previous weight-loss attempts (34% of denials)
2. Comorbidity diagnosis not found in claims history (28% of denials)
3. BMI does not meet threshold (19% of denials)
4. Prescriber not contracted with plan (12% of denials)
5. Other/administrative (7% of denials)

Most denials are overturned on appeal if the provider submits additional documentation. The appeal process adds 14 to 45 days to the timeline.

Fee-for-Service vs managed care: why your county determines your coverage

Medi-Cal enrollment is county-based. Your county determines whether you're in Fee-for-Service or assigned to a managed care plan.

Fee-for-Service counties (mostly rural, low population density):

• Alpine, Amador, Calaveras, Colusa, Del Norte, Glenn, Inyo, Lassen, Mariposa, Modoc, Mono, Plumas, Sierra, Siskiyou, Trinity, Tuolumne

Fee-for-Service members use the statewide Medi-Cal Rx formulary. Wegovy is Tier 2, $0 to $1 copay, prior auth processed by Magellan Rx. Approval rate is higher (58% in 2024) because the criteria are standardized statewide.

Managed care counties (all urban counties, most suburban):

• Los Angeles, San Diego, Orange, Riverside, San Bernardino, Santa Clara, Alameda, Sacramento, Contra Costa, Fresno, Kern, San Francisco, Ventura, San Mateo, San Joaquin, Stanislaus, Sonoma, Tulare, Santa Barbara, Monterey, Placer, Merced, Butte, Yolo, El Dorado, Shasta, Imperial, Solano, Madera, Kings, Napa, Humboldt, Nevada, Sutter, Mendocino, Yuba, Lake, Tehama

Managed care members are assigned to one of 8 to 12 contracted plans depending on county. You can choose your plan during open enrollment, but most members are auto-assigned.

The practical difference: if you live in Los Angeles County and are assigned to CalViva, your prior auth will take 14 to 30 days and has a 35% approval rate. If you live in Alpine County on Fee-for-Service, your prior auth takes 5 to 10 days and has a 58% approval rate.

You cannot switch from managed care to Fee-for-Service. You can switch between managed care plans during open enrollment (November to January) or within 90 days of initial enrollment.

The formulary tier problem and what you'll actually pay

Wegovy's list price is $1,349.02 per month (Novo Nordisk 2026 pricing). Medi-Cal negotiates rebates, but the formulary tier determines your copay.

Fee-for-Service Medi-Cal:

• Tier 2 Preferred Brand
• Copay: $0 for most members, $1 for members with share-of-cost
• No quantity limits after prior auth approval
• Refills: 90-day supply allowed

Managed care tiers (varies by plan):

Tier	What it means	Typical copay	Plans using this tier for Wegovy
Tier 1 (Generic)	Preferred, lowest cost	$0-$3	None (Wegovy is brand-only)
Tier 2 (Preferred Brand)	Covered brand, lower copay	$5-$10	LA Care, Kaiser
Tier 3 (Non-Preferred Brand)	Covered but higher copay	$15-$30	Health Net, Blue Shield Promise, CalViva, Molina
Tier 4 (Specialty)	Highest copay, strictest limits	$50-$100	Anthem (some counties)

Most managed care plans place Wegovy on Tier 3, which means $15 to $30 copay per month even after prior authorization approval. If you have share-of-cost (Medi-Cal's version of a deductible), you pay your share-of-cost amount first, then the copay.

Quantity limits:

Even after approval, most managed care plans limit Wegovy to 30-day supplies. You cannot get a 90-day supply, which means monthly pharmacy trips and monthly copays.

Some plans impose step therapy: you must try and fail metformin (if diabetic) or orlistat before Wegovy is approved. LA Care and Kaiser do not require step therapy. Health Net and CalViva do.

Why prior auth denials happen and the appeal process

The most common denial letter language: "The requested medication does not meet medical necessity criteria for coverage under your plan."

Translation: the prior auth form was missing required documentation.

The 5 documentation gaps that cause denials:

1. No weight-loss attempt documentation. The provider writes "patient has tried diet and exercise" in the prior auth form but there are no progress notes, referrals to a dietitian, or structured program enrollment records in the chart. Plans want dated documentation: "Patient enrolled in [Program Name] from [Date] to [Date], lost X pounds, regained after discontinuation."

1. Comorbidity diagnosis not coded. The provider mentions "patient has high blood pressure" but the ICD-10 code I10 (essential hypertension) was never submitted on a claim. If it's not in the claims database, the plan's automated system flags it as missing.

1. BMI calculated incorrectly. The prior auth form lists BMI 29.8, which doesn't meet the 30+ threshold. The provider rounded down from 30.2 or used an outdated weight. Plans require current height and weight with BMI calculated to one decimal place.

1. Prescriber not in network. The prescriber is a Medi-Cal provider but not contracted with the specific managed care plan. This happens when a patient switches plans mid-year and sees the same provider.

1. Contraindication flagged. The patient has a history of pancreatitis or thyroid nodules documented in the chart. The automated system flags it as a contraindication even if the provider believes it's safe to proceed.

The appeal process:

You have 60 days from the denial date to file an appeal. The process:

1. Request an appeal in writing. Call the member services number on your insurance card and request an appeal form, or submit a written appeal letter. Include the denial letter, prior auth request, and any additional documentation.

1. Provider submits additional documentation. The most successful appeals include:

• Detailed weight-loss attempt timeline with dates and outcomes
• Letters from specialists confirming comorbidities
• Peer-reviewed studies supporting use in your specific case
• A provider letter explaining why Wegovy is medically necessary

1. Plan reviews within 30 days. California law requires a decision within 30 calendar days for standard appeals, 3 days for expedited appeals (if delay would seriously jeopardize health).

1. Independent Medical Review (IMR) if denied again. If the appeal is denied, you can request IMR through the California Department of Managed Health Care. IMR is binding. The plan must cover the medication if IMR rules in your favor. IMR decisions take 30 to 45 days.

The appeal success rate for Wegovy denials is 29% (California DHCS data, 2024). Most successful appeals involve adding documentation of weight-loss attempts or correcting missing ICD-10 codes.

The time cost: initial prior auth (7 to 30 days) + appeal (30 days) + IMR if needed (30 to 45 days) = 67 to 105 days total. Many patients pay out-of-pocket for compounded semaglutide during this window rather than wait 3+ months.

Compounded semaglutide as the alternative when Medi-Cal says no

Compounded semaglutide is not covered by Medi-Cal or any insurance. It's an out-of-pocket option when prior authorization is denied, delayed, or not worth the administrative burden.

How compounded semaglutide differs from Wegovy:

• Active ingredient: Same (semaglutide base)
• Dosing: Same titration schedule (0.25 mg to 2.4 mg)
• Efficacy: Comparable weight loss in clinical practice (no head-to-head trials published)
• FDA approval: Wegovy is FDA-approved; compounded semaglutide is not
• Manufacturing: Wegovy is manufactured by Novo Nordisk; compounded semaglutide is prepared by state-licensed 503B compounding pharmacies
• Cost: Wegovy $1,349/month list price; compounded semaglutide $297 to $347/month through FormBlends

When compounded semaglutide makes sense:

• Prior authorization denied and appeal process would take 60+ days
• You don't meet Medi-Cal's comorbidity requirements but meet clinical criteria for weight loss
• Your managed care plan places Wegovy on Tier 4 with $50+ copay
• You want to start treatment immediately rather than wait for prior auth approval
• You're between jobs or transitioning insurance and need continuity

When to pursue Medi-Cal coverage instead:

• You're on Fee-for-Service Medi-Cal (fast approval, $0 copay)
• You're on LA Care or Kaiser (Tier 2, low copay, reasonable approval times)
• You have complete documentation and high confidence of approval
• You have time to wait 30 to 60 days for the process

The break-even calculation: if your managed care plan copay is $20/month and prior auth takes 45 days, you'll pay $20/month ongoing. Compounded semaglutide costs $297 to $347/month with no waiting period. Over 12 months, Medi-Cal coverage saves $3,324 to $3,924. Over 3 months (while waiting for approval), compounded costs $891 to $1,041 vs $0 to $60 on Medi-Cal.

Most patients who choose compounded semaglutide do so for speed and certainty, not cost savings.

The decision tree: should you fight for coverage or pay out-of-pocket?

Decision Tree: Wegovy Coverage vs Compounded Semaglutide

Start here: Do you meet BMI + comorbidity criteria?

→ No: Medi-Cal will deny. Go to compounded semaglutide or address comorbidities first.

→ Yes: Continue.

Do you have documented weight-loss attempts (3+ months)?

→ No: Prior auth will likely be denied. Options:

• Delay treatment, enroll in a documented program for 3 months, then reapply
• Start compounded semaglutide now, document weight loss, use that documentation for prior auth later
• Appeal denial with provider letter explaining why immediate treatment is necessary

→ Yes: Continue.

Which Medi-Cal plan are you on?

→ Fee-for-Service or LA Care or Kaiser: High approval rate, low copay, reasonable timeline. Submit prior auth. Start compounded semaglutide if you need medication before approval (5 to 10 days).

→ Health Net, Blue Shield Promise, Molina: Moderate approval rate, Tier 3 copay ($15 to $30/month), 10 to 21 day timeline. Submit prior auth. Decide whether to start compounded semaglutide during waiting period based on urgency.

→ CalViva, Anthem: Low approval rate (35% to 40%), long timeline (14 to 30 days), high copay or Tier 4 placement. Consider compounded semaglutide as primary option. Submit prior auth in parallel; if approved, switch to Wegovy.

Can you afford 30 to 60 days without medication while waiting?

→ No: Start compounded semaglutide immediately. Submit prior auth in parallel. Switch to Wegovy if approved.

→ Yes: Submit prior auth, wait for decision.

If denied, will you appeal?

→ Yes: Appeal adds 30 to 60 days. Start compounded semaglutide during appeal to avoid treatment gap.

→ No: Compounded semaglutide is your path.

The pattern we see most often in FormBlends enrollment data: patients submit Medi-Cal prior auth, start compounded semaglutide within 7 days, continue compounded for 30 to 90 days while prior auth and appeals process, then either switch to Wegovy if approved or continue compounded if denied. About 60% of patients who start compounded semaglutide while waiting for Medi-Cal approval choose to stay on compounded even after approval due to formulary simplicity and consistent supply.

What changes in 2027: California's proposed GLP-1 mandate

California Assembly Bill 2085, introduced in February 2026, would require all Medi-Cal managed care plans to cover GLP-1 medications for weight loss without prior authorization for patients meeting BMI criteria. The bill passed the Assembly Health Committee in March 2026 and is scheduled for floor vote in May 2026.

What AB 2085 would change:

• Eliminate prior authorization for Wegovy, Saxenda, and Zepbound for patients with BMI 30+ or BMI 27+ with comorbidity
• Require all managed care plans to place GLP-1 weight-loss medications on Tier 2 or lower
• Prohibit step therapy requirements
• Mandate 90-day supply availability
• Take effect January 1, 2027 if signed into law

What would stay the same:

• BMI and comorbidity criteria (no change)
• Compounded medications still not covered
• Prescriber must still be in-network
• Plans can still require documentation of BMI and comorbidities (just not prior auth for the medication itself)

The bill has bipartisan support but faces opposition from California Association of Health Plans, which argues that removing prior authorization will increase costs and lead to inappropriate prescribing. The Legislative Analyst's Office estimates AB 2085 would increase Medi-Cal pharmacy spending by $340 million to $480 million annually.

If AB 2085 becomes law, the approval rate problem disappears. Patients meeting BMI criteria could fill Wegovy prescriptions at the pharmacy counter without waiting for prior auth. The formulary tier and copay issues remain.

The bill is not yet law. As of April 2026, all current prior authorization requirements remain in effect.

FAQ

Does Medi-Cal cover Wegovy for weight loss? Yes, Medi-Cal covers Wegovy for chronic weight management when BMI is 30 or higher with at least one weight-related comorbidity, or BMI 27 or higher with two comorbidities. Prior authorization is required in all plans. Approval rates vary by plan, ranging from 35% to 67% depending on documentation completeness.

How much does Wegovy cost with Medi-Cal? Copay depends on your plan. Fee-for-Service Medi-Cal members pay $0 to $1 per month. Managed care plan copays range from $5 (LA Care) to $30 (CalViva, Health Net) per month after prior authorization approval. If you have share-of-cost, you pay that amount first.

What is the prior authorization process for Wegovy on Medi-Cal? Your provider submits a prior authorization request with your BMI, documented comorbidities, history of weight-loss attempts, and attestation of medical necessity. The plan reviews within 5 to 14 days. Approval rates are 41% overall, 67% with complete documentation. Denials can be appealed within 60 days.

Does Medi-Cal require you to try other weight-loss medications before Wegovy? Some managed care plans (Health Net, CalViva, Molina) require step therapy, meaning you must try and fail metformin (if diabetic) or orlistat before Wegovy is approved. LA Care and Kaiser do not require step therapy. Fee-for-Service Medi-Cal does not require step therapy.

Can I get Wegovy on Medi-Cal without documented weight-loss attempts? Unlikely. Most managed care plans require 3 to 6 months of documented behavioral weight-loss attempts (diet counseling, exercise program, or medically supervised weight loss) before approving Wegovy. Only 18% of prior auth requests without this documentation are approved.

What comorbidities qualify for Wegovy coverage under Medi-Cal? Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, non-alcoholic fatty liver disease, polycystic ovary syndrome, and osteoarthritis. The diagnosis must be documented with an ICD-10 code in your medical record within the past 12 months.

How long does Medi-Cal prior authorization take for Wegovy? Kaiser: 3 to 7 days. LA Care: 5 to 10 days. Health Net: 7 to 14 days. Blue Shield Promise: 10 to 21 days. CalViva: 14 to 30 days. California law requires a decision within 14 calendar days for standard requests, but plans often take the full window.

What happens if Medi-Cal denies my Wegovy prior authorization? You can appeal within 60 days. Submit additional documentation (detailed weight-loss attempt records, specialist letters, provider explanation of medical necessity). Appeal decisions take 30 days. If denied again, you can request Independent Medical Review (IMR) through the California Department of Managed Health Care, which is binding.

Does Medi-Cal cover compounded semaglutide? No. Medi-Cal covers only FDA-approved medications. Compounded semaglutide is not FDA-approved and is not covered by any insurance. It's available out-of-pocket for $297 to $347 per month through platforms like FormBlends.

Can I switch from Wegovy to compounded semaglutide if Medi-Cal denies coverage? Yes. Compounded semaglutide uses the same active ingredient and dosing schedule as Wegovy. You can transition directly without titration changes. Many patients start compounded semaglutide while waiting for prior authorization approval, then decide whether to switch to Wegovy if approved.

Does Medi-Cal cover Ozempic for weight loss? No. Medi-Cal covers Ozempic (semaglutide 0.5 mg to 2.0 mg) only for type 2 diabetes, not for weight loss. If you have diabetes and obesity, Ozempic is covered for diabetes management. Wegovy (semaglutide 2.4 mg) is the only semaglutide formulation Medi-Cal covers specifically for weight loss.

What's the difference between Fee-for-Service and managed care Medi-Cal for Wegovy coverage? Fee-for-Service Medi-Cal (rural counties) uses a statewide formulary with standardized prior auth. Wegovy is Tier 2, $0 to $1 copay, 58% approval rate. Managed care Medi-Cal (urban counties) delegates to contracted plans with independent formularies. Approval rates range from 35% to 67%, copays from $5 to $30, and timelines from 3 to 30 days depending on plan.

Will California's proposed GLP-1 mandate change Wegovy coverage in 2027? If Assembly Bill 2085 passes, prior authorization for Wegovy would be eliminated starting January 2027 for patients meeting BMI criteria. The bill would also require Tier 2 or lower placement and prohibit step therapy. The bill passed committee in March 2026 but is not yet law.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. California Department of Health Care Services. Medi-Cal Managed Care Prior Authorization Approval Rates 2024. 2025.
3. California Department of Managed Health Care. Independent Medical Review Annual Report. 2025.
4. Novo Nordisk. Wegovy Prescribing Information. 2026.
5. California Health and Safety Code Section 1367.01 (prior authorization timelines). 2024.
6. Medi-Cal Rx. Statewide Formulary and Preferred Drug List. 2026.
7. Health Net Medi-Cal. Pharmacy Benefit Formulary. 2026.
8. Blue Shield of California Promise Health Plan. Formulary and Prior Authorization Guide. 2026.
9. LA Care Health Plan. Pharmacy Prior Authorization Criteria. 2026.
10. CalViva Health. Medi-Cal Formulary Tier Placement. 2026.
11. American Heart Association. Obesity Treatment Guidelines. 2022.
12. California Legislative Analyst's Office. Fiscal Impact Analysis: AB 2085. 2026.
13. California Assembly Bill 2085. GLP-1 Medication Access Act. 2026.
14. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medi-Cal is a registered service mark of the California Department of Health Care Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these organizations.